Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder with complex symptomology. In addition to a predisposition to tumors, children with NF1 can present with reduced muscle mass, global muscle weakness, and impaired motor skills, which can have a significant impact on quality of life. Genetic mouse models have shown a lipid storage disease phenotype may underlie muscle weakness in NF1. Herein we confirm that biopsy specimens from six individuals with NF1 similarly manifest features of a lipid storage myopathy, with marked accumulation of intramyocellular lipid, fibrosis, and mononuclear cell infiltrates. Intramyocellular lipid was also correlated with reductions in neurofibromin protein expression by western analysis. An RNASeq profile of Nf1 null muscle from a muscle-specific Nf1 knockout mouse (Nf1 ) recapitulated all observed features of human NF1 myopathy, including lipid storage, fibrosis, and muscle weakness. Collectively, these insights led to the evaluation of a dietary intervention of reduced LCFAs, and enrichment of medium-chain fatty acids (MCFAs) with L-carnitine. Following 8-weeks of dietary treatment, Nf1 À=À Prx1 mice showed a 45% increase in maximal grip strength, and a 71% reduction in intramyocellular lipid staining compared with littermates fed standard chow. These data link NF1 deficiency to fundamental shifts in muscle metabolism, and provide strong proof of principal that a dietary intervention can ameliorate symptoms.
Introduction
Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disease with an incidence of 1: 3000 (1) . It features multiple manifestations with a significant clinical impact, including tumor development, particularly neurofibromas and nerve tumors (2, 3) ; learning difficulties (4, 5) ; and musculoskeletal complications (6, 7) . Understanding the basis of musculoskeletal involvement is particularly complex, as the biology of bone, muscle, and nerves can all be affected in these individuals. Early reports of motor deficits in NF1 children (8, 9) were attributed to nerve dysfunction (10) , however, in recent years several clinical studies have identified features suggestive of a primary myopathy in NF1 that could affect motor function (7) . These include reduced muscle size (11) , impaired exercise capacity (12, 13) , and clinically-relevant muscle weakness (12, (14) (15) (16) . Notably, a recent dynamometry study showed strength reductions of 30-50% in isolated upper and lower limb muscles of NF1 children when compared with matched controls (14) . This is consistent with anecdotal clinical reports of weakness and fatigue having a major impact on quality of life for affected individuals.
The NF1 protein product neurofibromin is a Ras GTPaseactivating protein with a key role in lineage specification and cell differentiation (2, 17) . Loss of neurofibromin impairs osteoblastic differentiation, and localized double inactivation of the NF1 gene has been associated with congenital tibial dysplasia (18, 19) . Neurofibromin is also up regulated during myoblast differentiation (20) , and global Nf1 inactivation in mice is embryonically lethal paralleled by impaired cardiac and skeletal muscle development (21) . Recent work aimed at understanding muscle weakness in NF1 has indicated a specific metabolic deficiency may be contributing (22) . Muscle-specific inactivation of murine Nf1 using the MyoD-Cre transgene (Nf1 MyoD À/À ) resulted in marked intramyocellular lipid accumulation in neonatal muscle, with no changes to sarcomeric structure (22) . Furthermore, Nf1 Prx1 À/À mice lacking Nf1 in the mesenchymal tissues of the limbs showed reduced levels of key mitochondrial lipid transporters CD36, carnitine palmitoyltransferase I (CPT1) and fatty acid transport protein 4 (FATP4) in muscle extracts (22) . In this study, we demonstrate human NF1 muscle biopsies are similarly characterized by features of a metabolic myopathy, including neutral lipid accumulations and fibrosis. Molecular studies in murine tissues highlight a shift in muscle metabolism towards increased glycolysis and reduced LCFA metabolism in Nf1 null muscle. Importantly, in subsequent histological and functional studies, we establish that Nf1 Prx1 À/À mice recapitulate the human NF1 myopathy, and that a dietary intervention enriched for MCFAs and L-carnitine effectively rescues lipid accumulation and muscle weakness in knockout mice. This illuminates an exciting therapeutic strategy that may provide benefit for individuals affected by NF1.
Results

Analysis of human NF1 muscle biopsies finds features of myopathy and lipid storage
Six muscle biopsies from individuals with a clinical diagnosis of NF1 (Table 1) were analysed for features muscle disease. H&E staining showed very few centralized nuclei, which are a common feature of degenerating/regenerating or dystrophic muscle (23) , however, substantial endomysial fibrosis and numerous infiltrating mononuclear cells were observed in NF1 samples (Fig. 1A,  Supplementary Material, Fig. S1 ). Oil Red O staining showed ¼0.81). For densitometric and statistical analysis of protein bands, NF1 sample #1 was excluded due to potential degradation ( Fig. 2A, Lane 3) ; however, we note that we observed the lowest neurofibromin levels and corresponding highest lipid levels in this specimen. Table S1 ). Of the top 30 most altered genes, 26 were identified as having a metabolic regulatory role by gene ontology (P < 0.05, Fig. 3B ). Pathway analysis of the entire RNAseq dataset highlighted glycolysis and gluconeogenic metabolism, focal-adhesion-PI3K-AKT-mTOR signaling, and WNT signaling as significantly affected (P < 0.01) ( Table 2) . Specifically, a 26-fold increase in the expression of the Slc2a3 glucose transporter was observed (P < 0.05).
Analysis of the
Protein kinase array studies showed significantly altered activity of key signaling kinases in Nf1 null muscle, including reduced protein-kinase B (AKT), increased c-Jun N-terminal kinase (JNK) activation, and reduced glycogen synthase kinase3a (GSK-3a) levels (Fig. 3C) . Notably, MEK/ERK phosphorylation was unaltered between WT and KO muscle in the kinase array (Fig. 3C ). This result was confirmed by western analysis (Fig. 3D (Table 3 ). In contrast, phospholipid and sphingolipid profiles were unaltered between Nf1 MyoD À/À and WT mouse muscle ( Fig. 4C ). LC-MS neutral lipid quantification found a trend towards increased total TAG ( Fig. 4D ) (P ¼ 0.054), and findings of significantly increased total CEs ( Fig. 4E ) (n ¼ 6, P < 0.01) were externally validated by biochemical assay (Supplementary Material, Fig. S3A ) (n ¼ 3, P < 0.05). Subsequent fatty acid analysis using gas-chromatography mass spectrometry (GC-MS) confirmed substantial increases in LCFA species (!C16: 0) in Nf1 MyoD À/À muscle compared with WT (Table 3) .
Limb-specific knockout of murine Nf1 recapitulates human NF1 myopathy
Nf1 Prx1
À/À knockout mice were generated with Nf1 developmentally absent from the limb mesenchyme and persistently deleted in muscle, bone, cartilage, adipose, and fibrous tissue of the fore and hind limbs (24) . Nf1 Prx1 À/À mouse muscle recapitulated all observed pathological features of human NF1-muscle biopsies, including endomysial fibrosis and intramyocellular lipid accumulation by histological staining (Fig. 5A ). Increased total lipid content was quantified by biochemical assays for total TAG and cholesterol content ( Fig. 5B and C). Functionally, Nf1 Prx1 À/À mice presented with significantly reduced grip strength compared with WT littermates (Fig. 5D , n ¼ 10, P < 0.001), and this strongly correlated with increased muscle lipid content (Fig. 5E , n ¼ 5, P < 0.01, R 2 ¼0.74). Notably, while altered muscle fiber type characteristics are sometimes observed in myopathic muscle (23) , descriptive fiber-type immunofluorescence staining on serial sections from Nf1 Prx1
quadriceps muscle showed no evidence of a shift in fiber-type, fiber-size, or evidence of fiber type grouping (Fig. 5F , n ¼ 3); confirming lipid accumulation is not associated with a denervation/ atrophy-like phenotype, nor to a shift to a phenotypically slower muscle.
Myopathic features of Nf1 Prx1
À/À mice are rescued by dietary intervention
Based on the changes in gene expression and protein kinase activity associated with glycolysis, as well as the changes in LCFA levels, it was hypothesized that a specific metabolic deficiency may plausibly underlie muscle weakness. LCFAs require active transport by the carnitine system across mitochondrial membranes for oxidative metabolism, while MCFAs can enter mitochondria by passive diffusion and are more rapidly metabolized (25,26). Thus, a diet enriched with MCFAs, reduced in LCFAs, and augmented by carnitine was trialed. The modified dietary formulation was based on standard laboratory rodent chow, and was designed to contain equal amounts digestible energy (15.7 MJ/kg), carbohydrates (65.6%), protein (13.8%), and total fat (4%). However, in contrast to standard chow where all lipids contain LCFAs (!C16: 0), the modified formulation contained 70% MCFAs (chiefly C8: 0). L-carnitine was also added to the MCFA enriched diet to support endogenous LCFA trafficking, at a calculated daily dose of 300mg/kg/ mouse/day. Following 8 weeks of ad libitum access to the MCFA enriched diet, Nf1 Prx1 À/À mice showed a 45% increase in muscle strength compared with mice fed standard chow ( Fig. 6A ) (n ¼ 10, P < 0.01). Increased strength was not associated with changes in bodyweight, muscle weight, or muscle weight to bodyweight ratio (Supplementary Material, Fig. 3B ). Reductions in muscle lipid were quantified across all specimens using whole section image analysis following Oil Red O staining. The data showed a significant 71% reduction in intramyocellular lipid accumulation in mid-belly muscle cross sections (Fig. 6B ) (n ¼ 10, P < 0.001).
Representative sections are shown (Fig. 6C) , which illustrate the muscle. P-values assessed by two-tailed student's t-Test. *P < 0.05, **P < 0.001, ***P < 0.0001.
striking differences in intramyocellular lipid at a macroscopic and microscopic level.
Discussion
Clinically-relevant muscle weakness, reduced muscle size, and poor motor control are becoming increasingly recognized as comorbidities for patients with NF1 (11) (12) (13) (14) (15) (16) . However, no studies to date have been able to identify an underlying biomechanical or biochemical mechanism. In this paper, we describe that muscle from NF1 individuals show evidence of an underlying lipid storage disease likely related to a defect in metabolism of LCFAs.
The parallels between human NF1 biopsies and murine muscle models are notable in several respects, including the common features of fibrosis and neutral lipid accumulations. This supports a similar underlying mechanism, however, the dysregulation seen in the Nf1 murine models appears more significant than in human biopsies. Genetically, the Nf1 MyoD À/À and
Nf1 Prx1
À/À models feature double inactivation of the Nf1 allele, whereas the human muscle biopsies are likely to be heterozygous for NF1 mutation. While some of the features of NF1 are associated with somatic mosaicism for double inactivation of the NF1 gene (i.e. neurofibromas, pseudarthrosis) (19, 27) , there is no evidence to date to indicate this is the case for muscle. Mouse models of Nf1 double inactivation have previously been used to study the mechanism of neurofibromin action in other tissues, such as bone. For example, Nf1 heterozygosity does not recapitulate the low bone density or bone dysplasias seen in individuals with NF1 (22), however, osteoprogenitor and osteoblast-specific Nf1 À/À knockout mice were able to reveal critical new signalling pathways (18, 28 (29, 30) suggesting these effects are independent of muscle. This may be directly attributed to the loss of NF1 in adipocytes and fibroblasts. Another important caveat is that NF1 muscle specimens were sourced from patients undergoing surgery for other indications (detailed in methods), such as for a pseudarthrosis (5/6 subjects). Thus, any muscle disuse prior to biopsy may be at least partially responsible for the increased intramuscular triglyceride (31). Nevertheless, both animal models and human specimens showed prominent intramyocellular lipid staining, and all models lacked substantial regenerative centralized nuclei or shifts in fiber-type or fiber size. Another notable finding was a negative correlation between neurofibromin levels and neutral lipid levels in human NF1 muscle biopsies. This is consistent with a new mechanism identified in NF1 patient-derived neurons, where neurofibromin protein levels were found to strongly correlate with reduced dopamine levels (32) . While there are poor genotype-phenotype correlations in NF1, individual NF1 mutations were found in the aforementioned study to affect neurofibromin stability and levels differently. Thus, future expansion of our human cohort will enable us to address questions including the association between neurofibromin protein levels and myopathic features; the correlation of diet and/or lifestyle factors with lipid accumulation; as well as the effects of sex and age.
This study demonstrates the power and utility of transcriptomic and lipidomics technologies for the development of new therapeutic strategies. Taken together, both non-biased screening approaches indicated increased glucose metabolism to compensate for impaired fatty-acid utilization, a phenomenon previously reported in muscle (33) . LCFA accumulation is also a hallmark feature of lipid storage myopathies, and these also show increased glycolytic flux in response to impaired fatty acid oxidation and lipid storage (34, 35) . Moreover, our findings are consistent with an emerging narrative of metabolic dysfunction in NF1-deficient tissues. Metabolic changes and lipid droplet formation have been described in NF1-malignant peripheral nerve-sheath tumor cells (36) and Nf1 À/À mouse embryonic fibroblasts (37). However, contrary to this latter study, we found 
P-values were assessed by two-tailed Students t-test.
no changes in pERK1/2 activity in kinase assays ( Fig. 3C and D) or succinate dehydrogenase activity in Nf1 À/À muscle (22) .
These findings align with prior microarray studies of Nf1 Prx1
À/À muscle tissues (30) , suggesting MEK/ERK signaling is required early in development, but is less critical in later stage myotube formation. While the mechanistic studies show changes in pathways associated with increased glycolytic metabolism, it is unclear whether these are upstream or downstream of alterations in lipid metabolism. Functional rescue by reducing the LCFA burden (via MCFA substitution and carnitine supplementation) intrinsically suggests that NF1-Ras signaling in muscle is critical for mitochondrial oxidative breakdown of long-chain fatty acids. However, mitochondrial enzyme function in Nf1 MyoD À/À muscle is not altered from WT (22) .
The capacity to rescue the Nf1 Prx1 À/À muscle phenotype with dietary modification and high dose L-carnitine has important implications. The effects on the model were rapid, with a 45% increase in muscle strength and 71% reduction in intramyocellular lipid after only 8 weeks. While muscle strength was not restored to wild type levels, these mice have joint problems (24) and smaller body weight that may indirectly affect grip strength testing. These data are consistent with preclinical studies of the effects of MCFA versus LCFA feeding on improved muscle metabolism (38) . Effects likely mediated through increased mitochondrial respiration, improved glucose tolerance, and increased energy expenditure (38) . Furthermore, equivalent dietary modifications are well-established treatments for muscle indications in other metabolic myopathies (25, 39, 40) , making them attractive for rapid translation in an NF1 context. The efficacy of modified diet therapy in the context of NF1 may also extend more broadly to the RASopathies; other genetic diseases with affected Ras/MAPK signaling (e.g. Noonan syndrome, Costello syndrome, Cardiofaciocutaneous syndrome), which also present with skeletal muscle weakness (15).
Materials and Methods
Human muscle biopsies
Human NF1 muscle samples (Table 1) were sourced from individuals with a clinical diagnosis of NF1 through set protocols. All individuals with NF1 fulfilled NIH clinical diagnostic criteria for NF1 based on examination by a clinical geneticist (Author DS). Informed consent for muscle biopsy for research purposes was obtained, and the study approved by the University of Utah Institutional Review Board. NF1 muscle biopsies were collected during surgery for other NF1 indications. NF1 subjects 1-2, & 5-6 had right fibular and tibial pseudarthroses and were undergoing intermedullary rod placements at the time of biopsy. NF1 subject 3 had right leg tibial bowing with leg length discrepancy, eventuating in amputation at the time of biopsy. NF1 subject 4 had lower leg and foot plexiform neurofibroma and was amputated below the knee at the time of biopsy. Control muscle samples were sourced from the Institute of Neuroscience and Muscle Research at The Children's Hospital at Westmead NSW, Australia. The use of samples for this study was approved by the Children's Hospital at Westmead ethics committee. . All colonies were maintained on a C57/B6 background.
Mouse strains and husbandry
Cholesterol and triglyceride assays
Total cholesterols and triglycerides in muscle samples were assayed using standardized colorimetric assay kits as per manufacturer's instructions (Total cholesterol, Abcam Biotechnology) (Triglycerides GPO-PAP; Roche Diagnostics, Indianapolis, IN, USA).
MCFA enriched diet
For diet studies, female mice were grouped housed 2-5 mice per cage, and fed ad libitum either standard AIN93M rodent chow pellets, or modified diet chow pellets. The modified diet formulation was based on AIN93M and contained equal amounts digestible energy (15.7 MJ/Kg), carbohydrates (65.6%), and protein (13.8%) and total fat (4%). However, as a fat source, predominantly octanoic acid (C8: 0, 2.8%) was included such that 70% of the total fatty acids were MCFAs. The remaining LCFAs were reduced to minimum levels (Palmitic Acid 16: 0, 0.07%; Stearic Acid 18: 0, 0.03%; Oleic Acid 18: 1, 0.17%; Linoleic Acid 18: 2 n6, 0.61%; Linolenic Acid 18: 3 n3, 0.30%). In contrast, the standard AIN93M, contains 100% of fatty acids as !C16: 0. Palmitic Acid 16: 0, 0.17%; Stearic Acid 18: 0, 0.08%; Oleic Acid 18: 1, 2.22%; Gadoleic Acid 20: 1, 0.04%; Linoleic Acid 18: 2 n6, 0.86%; Linolenic Acid 18: 3 n3, 0.56%. L-carnitine was also added to the modified formulation, at a concentration of 1.71g/kg, achieving a desired daily dose of 300mg/kg/mouse/day based on standard chow consumption rates (Specialty Feeds, WA, Australia). 
RNAseq analysis
Proteome phosho-protein array
The mouse Proteome Profiler Phospho-MAPK Array Kit was used for protein array studies as per manufacturer's instructions (R&D Systems). 50mg of total protein was prepared in 4% SDS, 125mM Tris, pH8.8 lysis buffer and loaded on array membranes for analysis. Blot signal intensity was quantified using Image J Image analysis software.
Lipidomics
Please see the Supplementary Methods document for a complete description of lipidomics materials and methods. Briefly however, for LC-MS analysis lipids were extracted using a modified Bligh Dyer extraction protocol. Lipids were analysed using Agilent LC 1200 binary pump coupled with Ascentis express RP amide (50 Â2.1 mm, 1.8u), and separated lipid species were detected using Agilent QQQ 6410 mass spectrometer, using multiple reaction monitoring (MRM). For GC-MS fatty acid analysis, dried samples and dried fatty acid calibration mix were derivatised with 5 mL of Meth-Prep TM II (Grace Davison Discovery). The samples were then analysed on a GC-MS system comprised of a Gerstel 2.5.2 Autosampler, a 7890A Agilent gas chromatograph and a 5975C Agilent quadrupole mass spectrometer (Agilent, Santa Clara, USA) (43, 44) .
Histological staining
Muscle tissues were harvested from animals at cull, surface coated in Tissue-Tek V R O.C.T. Compound (Sakura Finetek USA), placed on a thin piece of tin foil and frozen in isopentane (2-methyl butane) supercooled in liquid nitrogen, and stored at À80 C. 8um sections were cut on a Leica CM1950 Clinical
Cryostat, and captured on Superfrost TM Plus Microscope Slides (Fisher Scientific, USA) and stored at 4 degrees Celsius prior to staining. H&E and Oil Red O staining were performed as previously published (22) . Quantification was done using Fiji ImageJ (45) , by quantifying total lipid stained red area as a percentage of total section area.
Western blotting and antibodies
Western blots were performed on muscle biopsies from human controls and people with NF1. Samples were prepared in 4% SDS, 125mM Tris, pH8.8 lysis buffer. Muscle tissues were cryosectioned (15-20 Â 8 mm sections) and collected for solubilisation. Samples were sonicated then heated to 94 C for 3 min.
Total protein content was determined using a BCA assay kit (Pierce 23225) with a BSA standard curve. 
Muscle fiber typing
Fiber typing was performed as previously described (46) (47) (48) . Briefly, serial transverse 8lm cryosections of mouse quadriceps muscle were freshly cut and blocked with 2% BSA for 10 min, followed by blocking with AffiniPure Fab fragment goat antimouse IgG (Jackson ImmunoResearch Laboratories Inc) for 1 h at room temperature to prevent cross reactivity with endogenous mouse antibodies. Sections were then incubated with an antibody to either slow myosin type 1 (MAB1628; Chemicon, 1: 300), myosin heavy chain 2A (SC71; DSHB, University of Iowa, neat) or myosin heavy chain 2B (BF-F3, DSHB, University of Iowa, USA, neat) overnight at 4 C. The following day sections were washed three times with PBS, reblocked, and incubated with either Alexa555 goat anti-mouse IgG (for MAB1628 and SC71, A21424, Molecular Probes, 1: 300) or Alexa555 goat antimouse IgM (for BF-F3, A-21426, Molecular Probes, 1: 300) for 2 h at room temperature. Sections were then washed and fixed with 3% PFA for 10 min. Finally, sections were washed, incubated with DAPI (1lg/ml) for 5 min at room temperature, washed again and mounted with coverslips using Immu-Mount mounting reagent (ThermoScientific). Sections were imaged using a Leica SP5 scanning confocal microscope with a 20Â/0.7 NAobjective lens.
Grip strength testing
Grip strength testing was performed using a specialty mouse grip strength tester (Columbus instruments). Grip strength (peak force in Newtons) was measured in 3 sets of 5 efforts, with a 20 s rest between sets; for a total of 15 measures. The highest and lowest readings were excluded, and remaining readings were averaged. To ensure unbiased reliable testing, an experienced technician performed all testing for the study duration and was blinded to treatment group and mouse genotype.
Statistical analysis
Biological and technical replicates were conducted at least three times for all biochemical assays and histological staining experiments. Experimental results are expressed as mean 6 standard deviation (unless otherwise specified). Where two groups were compared, statistical comparisons were made using parametric two-tailed Student's t-tests. Multiple group comparisons were done using ANOVA with Tukey's post-hoc multiple comparisons test. P-values of 0.05 were considered statistically significant.
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